Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Dermatology (Basel, Switzerland)|June 27, 2024
Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3Rodney Sinclair, Ernest H Law, Xingqi Zhang, et al.
Clinical Therapeutics|December 1, 2022
Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights StudyKatie Mycock, Kent A Hanson, Gavin Taylor-Stokes, et al.
The Journal of Dermatology|March 10, 2026
Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in JapanAkira Yuasa, Kazumasa Kamei, Shota Saito, et al.
International Journal of Dermatology|October 10, 2025
Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3Ernest H Law, Bintu Sherif, Arash Mostaghimi, et al.
Dermatology and Therapy|April 24, 2025
Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia AreataKent A Hanson, Sergio Vañó-Galván, Andrew Messenger, et al.
Clinical and Experimental Dermatology|September 19, 2025
Findings from the Assessment of real-world Disease characteristics and outcomes in Alopecia Areata in a Global non-Interventional Observational cohort (ADAAGIO) studyKeith L Davis, Andrew Messenger, Sergio Vañó-Galván, et al.
Dermatology and Therapy|April 10, 2025
Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class AnalysisKent A Hanson, Khaled Ezzedine, Jenny Austin, et al.
Journal of Health Economics and Outcomes Research|June 15, 2026
A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia AreataAshley S Cha-Silva, Kate H Zhang, Christopher N Graham, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 1, 2017
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational StudyZhou Zhou, Paresh Chaudhari, Hongbo Yang, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 26, 2025
A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision MakingJonathan Mauer, Chiara Whichello, Brett Hauber, et al.
Pageof 5